Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618059 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00618059 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 28 participants.
The verdict
NCT00618059, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Interventions
- DRUG Pilocarpine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-08 |
| Est. Completion | 2004-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618059
The ClinicalTrials.gov registry entry for NCT00618059 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pilocarpine is the first listed.
NCT00618059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618059 about?
NCT00618059 is a clinical study titled "Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions". The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
What is the current status of trial NCT00618059?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2004-08. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00618059?
The interventions under investigation include: Pilocarpine (DRUG).
Who is sponsoring clinical trial NCT00618059?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.